EP4347791A4 - MEDICINES FOR GENE AND GENE CELL-BASED THERAPY - Google Patents

MEDICINES FOR GENE AND GENE CELL-BASED THERAPY

Info

Publication number
EP4347791A4
EP4347791A4 EP22816533.8A EP22816533A EP4347791A4 EP 4347791 A4 EP4347791 A4 EP 4347791A4 EP 22816533 A EP22816533 A EP 22816533A EP 4347791 A4 EP4347791 A4 EP 4347791A4
Authority
EP
European Patent Office
Prior art keywords
gene
medicines
based therapy
cell
gene cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22816533.8A
Other languages
German (de)
French (fr)
Other versions
EP4347791A1 (en
Inventor
Ajsylu Ildarovna Mullagulova
Alisa Almazovna Shajmardanova
Dar'ya Sergeevna Chulpanova
Valeriya Valer'evna Solov'eva
Yana Olegovna Muhamedshina
Aleksandr Aleksandrovich Kostennikov
Al'bert Anatol'evich Rizvanov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Federal State Autonomus Educational Institution Of Higher Learning "kazan Volga Region Federal University"
Federal State Autonomus Educational Institution Of Higher Learning Kazan Volga Region Federal Univ
Original Assignee
Federal State Autonomus Educational Institution Of Higher Learning "kazan Volga Region Federal University"
Federal State Autonomus Educational Institution Of Higher Learning Kazan Volga Region Federal Univ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Federal State Autonomus Educational Institution Of Higher Learning "kazan Volga Region Federal University", Federal State Autonomus Educational Institution Of Higher Learning Kazan Volga Region Federal Univ filed Critical Federal State Autonomus Educational Institution Of Higher Learning "kazan Volga Region Federal University"
Publication of EP4347791A1 publication Critical patent/EP4347791A1/en
Publication of EP4347791A4 publication Critical patent/EP4347791A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06001—Arylsulfatase (3.1.6.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Psychiatry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
EP22816533.8A 2021-06-01 2022-05-27 MEDICINES FOR GENE AND GENE CELL-BASED THERAPY Pending EP4347791A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2021115696A RU2769577C1 (en) 2021-06-01 2021-06-01 Drug for the treatment of metachromatic leukodystrophy and a method for its treatment
PCT/RU2022/000180 WO2022255906A1 (en) 2021-06-01 2022-05-27 Drug for genetic and gene-cell-based therapy

Publications (2)

Publication Number Publication Date
EP4347791A1 EP4347791A1 (en) 2024-04-10
EP4347791A4 true EP4347791A4 (en) 2025-07-09

Family

ID=81076125

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22816533.8A Pending EP4347791A4 (en) 2021-06-01 2022-05-27 MEDICINES FOR GENE AND GENE CELL-BASED THERAPY

Country Status (3)

Country Link
EP (1) EP4347791A4 (en)
RU (1) RU2769577C1 (en)
WO (1) WO2022255906A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024079361A1 (en) * 2022-10-14 2024-04-18 Neuway Pharma Gmbh A PROTEIN- OR PEPTIDE-BASED CAPSULE (PPC), PREFERABLY A VLP, LOADED WITH A MESSENGER RNA (mRNA) AND A METHOD OF PRODUCTION AND PURIFICATION THEREOF
WO2025084951A1 (en) * 2023-10-16 2025-04-24 Joint Stock Company "Axelgen" Recombinant genetic construct, adeno-associated virus for the treatment of metachromatic leukodystrophy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3142932A1 (en) * 2019-06-10 2020-12-17 Homology Medicines, Inc. Adeno-associated virus compositions for arsa gene transfer and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013357812B2 (en) * 2012-12-11 2019-10-10 Centogene Gmbh Method for the diagnosis of metachromatic leukodystrophy
BR112021021908A2 (en) * 2019-05-03 2022-02-01 Univ Pennsylvania Useful compositions in the treatment of metachromatic leukodystrophy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3142932A1 (en) * 2019-06-10 2020-12-17 Homology Medicines, Inc. Adeno-associated virus compositions for arsa gene transfer and methods of use thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GOURAV ROY ET AL: "Passage Bio Announces Pre-Clinical Data Presentation at Annual ASGCT Meeting", 11 May 2021 (2021-05-11), pages 1 - 2, XP093279474, Retrieved from the Internet <URL:https://s203.q4cdn.com/877117837/files/doc_news/archive/7a3a2804-23f6-4ad1-98d5-a0828099c284.pdf> *
JUDITH B�HRINGER ET AL: "Enzymatic characterization of novel arylsulfatase A variants using human arylsulfatase A-deficient immortalized mesenchymal stromal cells", HUMAN MUTATION, JOHN WILEY & SONS, INC, US, vol. 38, no. 11, 6 September 2017 (2017-09-06), pages 1511 - 1520, XP071975898, ISSN: 1059-7794, DOI: 10.1002/HUMU.23306 *
See also references of WO2022255906A1 *
SHAIMARDANOVA ALISA A. ET AL: "Metachromatic Leukodystrophy: Diagnosis, Modeling, and Treatment Approaches", FRONTIERS IN MEDICINE, vol. 7, 1 January 2020 (2020-01-01), pages 576221, XP093041645, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7606900/pdf/fmed-07-576221.pdf> DOI: 10.3389/fmed.2020.576221 *
SWEENEY NATHAN PAUL ET AL: "Rapid and Efficient Stable Gene Transfer to Mesenchymal Stromal Cells Using a Modified Foamy Virus Vector", MOLECULAR THERAPY, vol. 24, no. 7, 1 July 2016 (2016-07-01), United States, pages 1227 - 1236, XP093279493, ISSN: 1525-0016, Retrieved from the Internet <URL:https://www.sciencedirect.com/science/article/pii/S1525001616303550> DOI: 10.1038/mt.2016.91 *

Also Published As

Publication number Publication date
RU2769577C1 (en) 2022-04-04
EP4347791A1 (en) 2024-04-10
WO2022255906A1 (en) 2022-12-08

Similar Documents

Publication Publication Date Title
EP4347791A4 (en) MEDICINES FOR GENE AND GENE CELL-BASED THERAPY
Terkeltaub et al. Novel evidence‐based colchicine dose‐reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P‐glycoprotein inhibitors
IL284835A (en) Pharmaceutical combination containing TNO155 and ribociclib
IL288755A (en) Preparations and methods for delivery carriers of biological substances
DK4054662T3 (en) HYDROPHILIC MEDICINAL PRODUCTS AND HYDRATION MEDIA FOR HYDRATION THEREOF
IL291191A (en) cdk inhibitors and their use as drugs
IL320856A (en) Pharmaceutical combinations and uses thereof
ZA202400656B (en) 6-aminopyrazolopyrimidine compound and pharmaceutical use thereof
EP4324438C0 (en) Cryogenic Physical Therapy Booth and Cryogenic Physical Therapy Booth System
IL297900B2 (en) Compound having kdm5 inhibitory activity and pharmaceutical use thereof
IL307997A (en) Pharmaceutical preparations and intravitreal drug delivery systems for the treatment of eye diseases
EP4449904A4 (en) AEROSOL DELIVERY SYSTEM AND NATATOR THEREFOR
JOP20230017A1 (en) Antibodies to amyloid beta
EP4071767A4 (en) PREDICTIVE DISPLAY SYSTEM AND TREATMENT PROCEDURES
EP3793446A4 (en) ULTRASOUND-MEDIATED GENE AND DRUG DELIVERY
EP3962878A4 (en) MONOLITHIC CERAMIC BODY AND SET
EP4396577A4 (en) INTEGRATED LATERAL FLOW BIOASSAY AND BIOSENSOR
EP4400117A4 (en) SCREENING PROCEDURES FOR SENOLYTIC DRUGS AND SENOLYTIC DRUG
EP4055175A4 (en) PROMOTORS FOR THE INNER HAIR CELLS OF THE COCHLEA AND USE THEREOF
EP4393501A4 (en) TRICYCLICAL POLYPEPTIDE-CONJUGATED MEDICINE AND USES THEREOF
IL279877A (en) Ibusidanib forms and pharmaceutical preparations
EP3677248A4 (en) ANTI-AGING AGENT FOR THE SKIN AND ANTI-AGING ASSOCIATED GENE EXPRESSION REGULATOR
EP4384256A4 (en) DRUG DISPENSING ORDER FOR EXTENDED DRUG DISPENSING AND CONCORDABILITY
IL271224A (en) Substances with an aminoglycoside structure and their use for the treatment of genetic diseases
EP3801493C0 (en) SYSTEM FOR SHAPING AND COATING PHARMACEUTICAL TABLETS

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20231221

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20250605

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 37/02 20060101ALI20250530BHEP

Ipc: A61P 25/28 20060101ALI20250530BHEP

Ipc: C12N 7/00 20060101ALI20250530BHEP

Ipc: C12N 15/861 20060101ALI20250530BHEP

Ipc: C12N 5/0775 20100101AFI20250530BHEP